[Localized cancer of the prostate. What to tell the patient?].
Answering the question from patients with adenocarcinoma of the prostate is always difficult; choice of radiation therapy (versus prostatectomy), indications of brachytherapy frequency and severity of acute and late effects as rate of survival, local control, are among the most frequent inquiries. A part of the answers are not evident of due lack, consensus and the physicians need to speak honestly and give the most appropriate responses without improving anxiety and fears of the patient.
Eschwège
F
F
Département de radiothérapie, Institut Gustave-Roussy, 94805 Villejuif, France.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology / Q000523:psychology* / Q000532:radiotherapy; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D001918:Brachytherapy / Q000009:adverse effects / Q000523:psychology; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D006801:Humans; D007258:Informed Consent; D008297:Male; D010342:Patient Acceptance of Health Care; D010817:Physician-Patient Relations; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000523:psychology* / Q000532:radiotherapy; D011878:Radiotherapy / Q000009:adverse effects / Q000379:methods / Q000523:psychology; D020266:Radiotherapy, Conformal / Q000009:adverse effects / Q000523:psychology; D014342:Truth Disclosure
D018931:Antineoplastic Agents, Hormonal